Ipca Laboratories Ltd Q2 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/lrdxbv5lk9p58g3a2142qwae.pdf

Key Takeaways


Unichem Integration & Turnaround

A. K. Jain: "we are very confident that what we had talked initially when we have announced the deal that we will be able to achieve almost around Rs.300 Crores kind of EBITDA on the Unichem side that is very much possible looking into all these details what we have done and once the market extension happens and we start marketing those products in various market definitely we can make Unichem as a beautiful company."

US Market Re-entry

Harish Kamath: "as far as the pricing is concerned in our product range there is hardly any reduction in the prices in that market so when we were there we were sharing almost 40% to 50% profit with the marketing partner. Now that issue is not there."

Domestic Formulation & Branded Markets


Export Generics & API


Biosimilars & R&D

A. K. Jain: "Looking at our R&D presentations and all we are getting values are much higher than currently what market is getting. That is what I can say but I cannot give the name of the production right now."

Margin & Profitability Outlook

Harish Kamath: "we are confident of telling and assuring the investors our EBITDA margin going forward should improve at least by 100 basis points year after year."

Guidance & Commitments

CommitmentSpecificsTimeline
Domestic formulation growth12% to 14% growth for the full yearFY24
Export generic growthAround 20% growth (revised from 7-8%)FY24
International branded business growthAround 12% growth (lowered)FY24
US market re-entryFirst shipments to US beginQ1 FY25
Unichem EBITDA targetAround ₹300 Crores EBITDAAbout two years
Unichem profitabilityIreland and UK markets to show no losses, possibly profitableCurrent year (FY24)
Unichem product launches11 new products launchableFY24
Unichem ANDA launchesNine ANDAsApril 2024 to March 2025
Unichem ANDA launches (incl. Para IV)Seven ANDAs including three Para IV2024 or 2025
Unichem API integration10-12 common APIs integrated into Unichem basket12 to 15 months
Unichem market extension24 ANDA products extended to new marketsAround 18 months (plus regulatory time)
R&D cost increaseFrom ~2.5% to up to 4% of revenueGoing forward (no end date)
EBITDA margin improvementAt least 100 bps improvement year after yearOngoing
Biosimilar plant completionPlant construction completeEnd of Q1 next year
Continuous process plant (Aurangabad)Commercial production startEnd-December
Devas plant Europe inspectionRegulatory inspectionYear-end or early next year

Key Metrics

MetricQ2 FY24
Domestic formulation growth~10% YoY, with two range jump over corresponding period
Market share (MAT basis)1.92%, improved from 1.89% as of mid-September 2023 per IQVIA
Branded promotional business revenue~₹146 cr, +15% YoY from ₹127 cr
Export generic business revenue~₹264 cr, +32% YoY from ₹200 cr
Institutional tender anti-malarial revenue~₹61 cr, -21% YoY from ₹77 cr
Overall export formulation revenue~₹470 cr, +16% YoY from ₹404 cr
API business revenue~₹335 cr, +6% YoY from ₹307 cr
Unichem consolidated topline (2 months)~₹285 cr, consolidated from August 1, 2023
Unichem consolidated bottom line (2 months)Loss of ~₹16 cr
Unichem EBITDA margin (2 months)~5%, positive
Standalone EBITDA margin20.86%, improved from 18.85% in Q2 FY23
Consolidated EBITDA margin17.64%, improved from 17% in Q2 FY23 despite two months of Unichem
Effective tax rate (IPCA standalone)~34%, including deferred tax, vs normal rate of ~25% plus 1-2% deferred tax
Net borrowing~₹800 cr, cost around 7%; gross borrowing ~₹1,600 cr with ~₹800 cr cash
MR productivity (monthly)~₹4,53,000, up from ₹4,18,000 last year